Phaseline

Companies › Sarepta Therapeutics

Sarepta Therapeutics: clinical trials, targets and expected readouts

4 active drug programs in 7 registered trials: 3 Phase 3, 3 Phase 1, 1 Phase 4; Neurology, Hematology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
delandistrogene moxeparvovec
Dystrophin exogenous gene
DMDPhase 4Duchenne Muscular DystrophyMay 2027
SRP-9003
Gene transfer therapy encoding beta-sarcoglycan (β-SG); scAAVrh74.MHCK7.hSGCB
SGCBPhase 3Limb-girdle Muscular Dystrophy; Limb Girdle Muscular DystrophyAug 2028
Eteplirsen
Dystrophin pre-mRNA positive modulator
DMDPhase 3Muscular Dystrophy, Duchenne–
SRP-1005–Phase 1Huntington's DiseaseNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03992430EteplirsenPhase 3Muscular Dystrophy, DuchenneHematologyOct 2026
NCT05881408delandistrogene moxeparvovecPhase 3Duchenne Muscular DystrophyNeurologyMay 2027
NCT07542314delandistrogene moxeparvovecPhase 4Duchenne Muscular DystrophyNeurologyAug 2027
NCT07536061SRP-1005Phase 1Huntington's DiseaseNeurologyNov 2027
NCT04626674delandistrogene moxeparvovecPhase 1Duchenne Muscular DystrophyNeurologyDec 2027
NCT05876780SRP-9003Phase 1Limb Girdle Muscular DystrophyNeurologyAug 2028
NCT06246513SRP-9003Phase 3Limb-girdle Muscular DystrophyNeurologyNov 2029

From the company's SEC filings

Cash and short-term investments of $879m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

DMD (2) SGCB (1)

Companies with the same targets

Solid Biosciences NS Pharma Dyne Therapeutics Avidity Biosciences REGENXBIO Precision BioSciences Wave Life Sciences USA Belief BioMed (Beijing) Insmed Gene Therapy Nippon Shinyaku

Companies built like this

Nippon Shinyaku NS Pharma Dyne Therapeutics Avidity Biosciences Navamedic

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.